Telbivudine
Telbivudine structure
|
Common Name | Telbivudine | ||
|---|---|---|---|---|
| CAS Number | 3424-98-4 | Molecular Weight | 242.229 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C10H14N2O5 | Melting Point | 188-190ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Cell Fusion Connects Oncogenesis with Tumor Evolution.
Am. J. Pathol. 185 , 2049-60, (2015) Cell fusion likely drives tumor evolution by undermining chromosomal and DNA stability and/or by generating phenotypic diversity; however, whether a cell fusion event can initiate malignancy and direct tumor evolution is unknown. We report that a fusion event... |
|
|
In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Antimicrob. Agents Chemother. 58(8) , 4431-42, (2014) The hepatitis C virus (HCV) nonstructural 5A (NS5A) protein is a clinically validated target for drugs designed to treat chronic HCV infection. This study evaluated the in vitro activity, selectivity, and resistance profile of a novel anti-HCV compound, samat... |
|
|
Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B.
Liver Int. 35(3) , 834-45, (2015) Nucleos(t)ide analogues (NAs) can indirectly restore host immunity against hepatitis B virus (HBV) by inhibiting virus replication. We aimed to investigate whether telbivudine could prevent HBV-related fibrosis progression by their influence on CD4(+) T-cell ... |
|
|
Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes.
Cancer Res. 74(11) , 3114-26, (2014) Cancer genomes maintain a complex array of somatic alterations required for maintenance and progression of the disease, posing a challenge to identify driver genes among this genetic disorder. Toward this end, we mapped regions of recurrent amplification in a... |
|
|
Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.
Clin. Drug Investig. 35(3) , 197-209, (2015) Several antiviral therapies are now available for patients with chronic hepatitis B (CHB), but the most cost-effective strategy for Chinese patients is unclear. The aim of this study was to estimate the long-term cost effectiveness of the antiviral treatments... |
|
|
Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment.
PLoS ONE 10 , e0144893, (2015) Current hepatocellular carcinoma (HCC) staging systems only use baseline characteristics to predict outcome. We aimed to explore modifiable factors of the prognosis in HCC cases had undergone non-surgical treatment.All HCC cases in Kaohsiung Chang Gung Memori... |
|
|
Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model.
Virol. J. 9 , 280, (2012) The effects of Hepatitis B virus (HBV) rtA181T/sW172* mutation on viral replication and pathogenicity was concerned recently. This study aimed to investigate the biological characteristics of rtA181T/sW172* mutant strain of HBV in animal model.The rtA181T/sW1... |
|
|
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.
Arch. Virol. 159 , 29-37, (2014) We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic r... |
|
|
Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism.
PLoS ONE 7(5) , e37724, (2012) To identify interactions a nucleoside analog library (NAL) consisting of 45 FDA-approved nucleoside analogs was screened against 23 enzymes of the human nucleotide metabolism using a thermal shift assay. The method was validated with deoxycytidine kinase; eig... |
|
|
Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study.
Clin. Gastroenterol. Hepatol. 13 , 1170-6, (2015) Hepatitis B virus (HBV) infection is a leading cause of liver diseases. We investigated the efficacy and safety of telbivudine in preventing transmission of HBV from hepatitis B e antigen-positive pregnant women with high viral loads to their infants in an op... |